{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T07:25:33Z","timestamp":1782458733475,"version":"3.54.5"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:00:00Z","timestamp":1623110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Apremilast monotherapy was evaluated up to 5\u2009years in PALACE 4 (fourth PsA Long-term Assessment of Clinical Efficacy study) DMARD-na\u00efve patients with PsA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with active PsA were randomized (1:1:1) to placebo, apremilast 30\u2009mg or apremilast 20\u2009mg twice a day. Placebo patients were rerandomized to apremilast at week 16 or 24. Double-blind apremilast continued to week 52, with a 4-year open-label extension (\u2264260\u2009weeks of exposure). Analyses through week 260 were based on observed data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 527 patients were treated. Among patients randomized to apremilast 30\u2009mg at baseline, 45.5% completed week 260. At study end, 24.8% reported conventional synthetic DMARD or steroid use for any reason. At week 260, 65.8%\/39.0%\/20.3% of apremilast 30\u2009mg patients achieved ACR20\/ACR50\/ACR70 responses, respectively. PsA sign and symptom improvements were sustained up to week 260 with continued treatment, including reductions in swollen (84.8%) and tender (76.4%) joint counts. Among apremilast 30\u2009mg patients with baseline enthesitis or dactylitis, 71.2% achieved a Maastricht Ankylosing Spondylitis Enthesitis Score of 0 and 95.1% achieved a dactylitis count of 0. Over 50% of patients achieved a HAQ Disability Index minimal clinically important difference (\u22650.35). In patients with \u22653% baseline psoriasis-involved body surface area, 60.3% and 47.6% achieved \u226550% and \u226575% improvement in Psoriasis Area and Severity Index scores, respectively. Patients continuing apremilast 20\u2009mg also demonstrated consistent, sustained improvements. The most common adverse events were diarrhoea, nausea, headache, upper respiratory tract infection and nasopharyngitis. No new safety concerns were observed long term.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Apremilast led to sustained PsA efficacy up to 260\u2009weeks and was well tolerated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>ClinicalTrials.gov (http:\/\/clinicaltrials.gov), NCT01307423.<\/jats:p><\/jats:sec>","DOI":"10.1093\/rheumatology\/keab449","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T11:40:30Z","timestamp":1623066030000},"page":"1035-1043","source":"Crossref","is-referenced-by-count":12,"title":["Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-na\u00efve patients"],"prefix":"10.1093","volume":"61","author":[{"given":"Alvin F","family":"Wells","sequence":"first","affiliation":[{"name":"Aurora Rheumatology and Immunotherapy Center, Franklin, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J","family":"Edwards","sequence":"additional","affiliation":[{"name":"NIHR Clinical Research Facility, University Hospital Southampton, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan J","family":"Kivitz","sequence":"additional","affiliation":[{"name":"Altoona Center for Clinical Research, Duncansville, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Bird","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Guerette","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Amgen Inc., Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolay","family":"Delev","sequence":"additional","affiliation":[{"name":"Clinical Development, Celgene Corporation, Summit, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Paris","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Amgen Inc., Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lichen","family":"Teng","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Amgen Inc., Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob A","family":"Aelion","sequence":"additional","affiliation":[{"name":"West Tennessee Research Institute, Jackson, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,6,8]]},"reference":[{"key":"2022030208231752300_keab449-B1","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis: treatment recommendations for psoriatic arthritis 2015","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2022030208231752300_keab449-B2","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022030208231752300_keab449-B3","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/rheumatology\/key032","article-title":"Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial","volume":"57","author":"Wells","year":"2018","journal-title":"Rheumatology (Oxford"},{"key":"2022030208231752300_keab449-B4","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2022030208231752300_keab449-B5","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"2022030208231752300_keab449-B6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2174\/1573397052954154","article-title":"Recent developments in management of psoriatic arthritis","volume":"1","author":"El Miedany","year":"2005","journal-title":"Curr Rheumatol Rev"},{"key":"2022030208231752300_keab449-B7","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.3899\/jrheum.110546","article-title":"Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction","volume":"38","author":"Mease","year":"2011","journal-title":"J Rheumatol"},{"key":"2022030208231752300_keab449-B8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/ard.62.2.127","article-title":"Assessment of enthesitis in ankylosing spondylitis","volume":"62","author":"Heuft-Dorenbosch","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"2022030208231752300_keab449-B9","first-page":"15","volume-title":"Incidence of nonmelanoma skin cancer in the United States","author":"Nonmelanoma skin cancer (Tables 1\u20139). In: Scotto","year":"1983"},{"key":"2022030208231752300_keab449-B10","first-page":"45"},{"key":"2022030208231752300_keab449-B11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"2018 American College of Rheumatology\/ National Psoriasis Foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2022030208231752300_keab449-B12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/annrheumdis-2012-201972","article-title":"Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA)","volume":"73","author":"Theander","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2022030208231752300_keab449-B13","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1136\/ard.2011.150938","article-title":"Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease?","volume":"70","author":"Gladman","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2022030208231752300_keab449-B14","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","article-title":"Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis","volume":"74","author":"Haroon","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2022030208231752300_keab449-B15","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1136\/annrheumdis-2012-202608","article-title":"Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis","volume":"72","author":"Tillett","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2022030208231752300_keab449-B16","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2022030208231752300_keab449-B17","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13075-019-1901-3","article-title":"Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis","volume":"21","author":"Kavanaugh","year":"2019","journal-title":"Arthritis Res Ther"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab449\/39310095\/keab449.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/3\/1035\/42672452\/keab449.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/3\/1035\/42672452\/keab449.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T16:25:54Z","timestamp":1699115154000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/3\/1035\/6294945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,8]]},"references-count":17,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,6,8]]},"published-print":{"date-parts":[[2022,3,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab449","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,1]]},"published":{"date-parts":[[2021,6,8]]}}}